For some patients with no hope, the potential of gene therapy represents a light at the end of the tunnel. Boosted by tremendous progress on multiple fronts, the gene therapy race is only intensifying with the FDA anticipating more than 200 gene therapy Investigational New Drugs (INDs) per year by 2020. This dynamic panel will feature industry leaders who are taking diverse approaches to competing in the new era of gene therapy. They will delve into new approaches related to developing and delivering genetic medicine, trends and partnering deals as well as discuss remaining scientific challenges and opportunities.
Sr. Director, Head of Strategic Analysis External Innovation, Discovery, Product Development and Supply
Janssen Research & Development, Pharmaceutical Companies of Johnson and Johnson